14 February 2025
Forthcoming 16th EU Russia sanctions package: What to expect?
1 min read
Our client alert provides an overview of the most notable new trade restrictions to be expected.
While discussions in the Council of the EU on the anticipated 16th sanctions package continue, details on the expected changes are gradually trickling in. The European Commission circulated its proposal for a 16th package in early February and we understand that the text is facing little substantial opposition from EU Member States so far. As a result, hope is raised within EU circles that the package can be adopted before the third anniversary of Russia’s invasion of Ukraine on 24 February 2025.
Our client alert below provides an overview of the most notable new trade restrictions to be expected.
Attachments:
->
News & insights
1 min
read
read
Briefings
VBB secures lowest anti-dumping duty for Hankook in EU passenger car tyre investigation
7 July 2026
2 min
read
read
Briefings
Lithuanian Competition Authority Fines Pharmacy Association and Individual Firms for Collusion while Participating in Margin-setting Procedure
14 December 2022
2 min
read
read
Briefings
France - Supreme Court Allows Follow-on Damages Action by Health Insurer in Wake of Sanofi’s Denigration Strategy against Generic Rivals
13 October 2023
2 min
read
read
Briefings
European Commission Sends Statement of Objections to Teva over Abusive Patent Filings and Disparagement of Generic Competitors
11 October 2022
1 min
read
read
Briefings
F. Hoffmann-La Roche and Novartis (Avastin - Lucentis) – ECJ Finds Concerted Efforts to Restrict Off-label Use of Medicinal Products Likely to Breach Competition Rules
24 January 2018
3 min
read
read
Briefings
Advocate General Recommends to Court of Justice of European Union to Allow Reimbursement of Off Label Use of Medicine for Purely Budgetary Reasons
30 August 2018
3 min
read
read
Briefings
“National Healthcare Insurance Systems Are Allowed To Reimburse Off-Label Use of Medicine” Says ECJ
21 November 2018
3 min
read
read
Briefings
French Competition Authority - Genentech, Novartis and Roche Fined EUR 444 million in Saga Involving Wet Age-Related Macular Degeneration
9 September 2020
